1
|
Xisto MF, Dias RS, Feitosa-Araujo E, Prates JWO, da Silva CC, de Paula SO. Efficient Plant Production of Recombinant NS1 Protein for Diagnosis of Dengue. FRONTIERS IN PLANT SCIENCE 2020; 11:581100. [PMID: 33193526 PMCID: PMC7649140 DOI: 10.3389/fpls.2020.581100] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Accepted: 10/02/2020] [Indexed: 05/28/2023]
Abstract
Dengue fever is endemic in more than 120 countries, which account for 3.9 billion people at risk of infection worldwide. The absence of a vaccine with effective protection against the four serotypes of this virus makes differential molecular diagnosis the key step for the correct treatment of the disease. Rapid and efficient diagnosis prevents progression to a more severe stage of this disease. Currently, the limiting factor in the manufacture of dengue (DENV) diagnostic kits is the lack of large-scale production of the non-structural 1 (NS1) protein (antigen) to be used in the capture of antibodies from the blood serum of infected patients. In this work, we use plant biotechnology and genetic engineering as tools for the study of protein production for research and commercial purposes. Gene transfer, integration and expression in plants is a valid strategy for obtaining large-scale and low-cost heterologous protein production. The authors produced NS1 protein of the dengue virus serotype 2 (NS1DENV2) in the Arabidopsis thaliana plant. Transgenic plants obtained by genetic transformation expressed the recombinant protein that was purified and characterized for diagnostic use. The yield was 203 μg of the recombinant protein per gram of fresh leaf. By in situ immunolocalization, transgenic protein was observed within the plant tissue, located in aggregates bodies. These antigens showed high sensitivity and specificity to both IgM (84.29% and 91.43%, respectively) and IgG (83.08% and 87.69%, respectively). The study goes a step further to validate the use of plants as a strategy for obtaining large-scale and efficient protein production to be used in dengue virus diagnostic tests.
Collapse
Affiliation(s)
| | - Roberto Sousa Dias
- Department of General Biology, Federal University of Viçosa, Viçosa, Brazil
| | | | | | | | | |
Collapse
|
2
|
Morgenfeld MM, Vater CF, Alfano EF, Boccardo NA, Bravo-Almonacid FF. Translocation from the chloroplast stroma into the thylakoid lumen allows expression of recombinant epidermal growth factor in transplastomic tobacco plants. Transgenic Res 2020; 29:295-305. [PMID: 32318934 DOI: 10.1007/s11248-020-00199-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2019] [Accepted: 04/13/2020] [Indexed: 12/20/2022]
Abstract
Chloroplast transformation has many potential advantages for the production of recombinant proteins in plants. However, it has been reported that chloroplast expression of many proteins, such as human epidermal growth factor (hEGF), results hindered by post-transcriptional mechanisms. hEGF degradation has been related to the redox potential of the stroma and protein misfolding. To solve this problem, we proposed the redirection of hEGF into the thylakoid lumen where the environment could improve disulfide bonds formation stabilizing the functional conformation of the protein. We generated transplastomic tobacco plants targeting hEGF protein to the thylakoid lumen by adding a transit peptide (Str). Following this approach, we could detect thylakoid lumen-targeted hEGF by western blotting while stromal accumulation of hEGF remained undetectable. Southern blot analysis confirmed the integration of the transgene through homologous recombination into the plastome. Northern blot analysis showed similar levels of egf transcripts in the EGF and StrEGF lines. These results suggest that higher stability of the hEGF peptide in the thylakoid lumen is the primary cause of the increased accumulation of the recombinant protein observed in StrEGF lines. They also highlight the necessity of exploring different sub-organellar destinations to improve the accumulation levels of a specific recombinant protein in plastids.
Collapse
Affiliation(s)
- Mauro M Morgenfeld
- Instituto de Ingeniería Genética y Biología Molecular "Dr, Héctor Torres" (INGEBI-CONICET), Vuelta de Obligado 2490, Ciudad Autónoma de Buenos Aires, Argentina
- Departamento de Fisiología, Biología Molecular y Celular (FCEN-UBA), Buenos Aires, Argentina
| | - Catalina F Vater
- Instituto de Ingeniería Genética y Biología Molecular "Dr, Héctor Torres" (INGEBI-CONICET), Vuelta de Obligado 2490, Ciudad Autónoma de Buenos Aires, Argentina
| | - E Federico Alfano
- Instituto de Ingeniería Genética y Biología Molecular "Dr, Héctor Torres" (INGEBI-CONICET), Vuelta de Obligado 2490, Ciudad Autónoma de Buenos Aires, Argentina
| | - Noelia A Boccardo
- Instituto de Ingeniería Genética y Biología Molecular "Dr, Héctor Torres" (INGEBI-CONICET), Vuelta de Obligado 2490, Ciudad Autónoma de Buenos Aires, Argentina
| | - Fernando F Bravo-Almonacid
- Instituto de Ingeniería Genética y Biología Molecular "Dr, Héctor Torres" (INGEBI-CONICET), Vuelta de Obligado 2490, Ciudad Autónoma de Buenos Aires, Argentina.
- Departamento de Ciencia y Tecnología, Universidad Nacional de Quilmes, Bernal, Buenos Aires, Argentina.
| |
Collapse
|
3
|
Drake PMW, Szeto TH, Paul MJ, Teh AYH, Ma JKC. Recombinant biologic products versus nutraceuticals from plants - a regulatory choice? Br J Clin Pharmacol 2016; 83:82-87. [PMID: 27297459 DOI: 10.1111/bcp.13041] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Revised: 06/09/2016] [Accepted: 06/10/2016] [Indexed: 01/26/2023] Open
Abstract
Biotechnology has transformed the potential for plants to be a manufacturing source of pharmaceutical compounds. Now, with transgenic and transient expression techniques, virtually any biologic, including vaccines and therapeutics, could be manufactured in plants. However, uncertainty over the regulatory path for such new pharmaceuticals has been a deterrent. Consideration has been given to using alternative regulatory paths, including those for nutraceuticals or cosmetic agents. This review will consider these possibilities, and discuss the difficulties in establishing regulatory guidelines for new pharmaceutical manufacturing technologies.
Collapse
Affiliation(s)
- Pascal M W Drake
- Institute for Infection and Immunity, St. George's Hospital Medical School, London, SW17 0RE, UK
| | - Tim H Szeto
- Institute for Infection and Immunity, St. George's Hospital Medical School, London, SW17 0RE, UK
| | - Mathew J Paul
- Institute for Infection and Immunity, St. George's Hospital Medical School, London, SW17 0RE, UK
| | - Audrey Y-H Teh
- Institute for Infection and Immunity, St. George's Hospital Medical School, London, SW17 0RE, UK
| | - Julian K-C Ma
- Institute for Infection and Immunity, St. George's Hospital Medical School, London, SW17 0RE, UK
| |
Collapse
|
4
|
Moustafa K, Makhzoum A, Trémouillaux-Guiller J. Molecular farming on rescue of pharma industry for next generations. Crit Rev Biotechnol 2015; 36:840-50. [DOI: 10.3109/07388551.2015.1049934] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
5
|
Zhang L, Shi J, Jiang D, Stupak J, Ou J, Qiu Q, An N, Li J, Yang D. Expression and characterization of recombinant human alpha-antitrypsin in transgenic rice seed. J Biotechnol 2013; 164:300-8. [DOI: 10.1016/j.jbiotec.2013.01.008] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2012] [Revised: 01/12/2013] [Accepted: 01/17/2013] [Indexed: 01/03/2023]
|
6
|
Wilken LR, Nikolov ZL. Process evaluations and economic analyses of recombinant human lysozyme and hen egg-white lysozyme purifications. Biotechnol Prog 2011; 27:733-43. [PMID: 21574265 DOI: 10.1002/btpr.593] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2010] [Revised: 02/26/2011] [Indexed: 11/12/2022]
Abstract
Human lysozyme and hen egg-white lysozyme have antibacterial, antiviral, and antifungal properties with numerous potential commercial applications. Currently, hen egg-white lysozyme dominates low cost applications but the recent high-level expression of human lysozyme in rice could provide an economical source of lysozyme. This work compares human lysozyme and hen egg-white lysozyme adsorption to the cation exchange resin, SP-Sepharose FF, and the effect of rice extract components on lysozyme purification. With one exception, the dynamic binding capacities of human lysozyme were lower than those of hen egg-white at pH 4.5, 6, and 7.5 with ionic strengths ranging from 0 to 100 mM (5-20 mS). Ionic strength and pH had a similar effect on the adsorption capacities, but human lysozyme was more sensitive to these two factors than hen egg-white lysozyme. In the presence of rice extract, the dynamic binding capacities of human and hen egg-white lysozymes were reduced by 20-30% and by 32-39% at pH 6. Hen egg-white lysozyme was used as a benchmark to compare the effectiveness of human lysozyme purification from transgenic rice extract. Process simulation and cost analyses for human lysozyme purification from rice and hen egg-white lysozyme purification from egg-white resulted in similar unit production costs at 1 ton per year scale.
Collapse
Affiliation(s)
- Lisa R Wilken
- Dept. of Biological & Agricultural Engineering, Texas A&M University, College Station, TX 77843, USA
| | | |
Collapse
|
7
|
Abstract
Recombinant protein pharmaceuticals are now widely used in treatment of chronic diseases, and several recombinant protein subunit vaccines are approved for human and veterinary use. With growing demand for complex protein pharmaceuticals, such as monoclonal antibodies, manufacturing capacity is becoming limited. There is increasing need for safe, scalable, and economical alternatives to mammalian cell culture-based manufacturing systems, which require substantial capital investment for new manufacturing facilities. Since a seminal paper reporting immunoglobulin expression in transgenic plants was published in 1989, there have been many technological advances in plant expression systems to the present time where production of proteins in leaf tissues of nonfood crops such as Nicotiana species is considered a viable alternative. In particular, transient expression systems derived from recombinant plant viral vectors offer opportunities for rapid expression screening, construct optimization, and expression scale-up. Extraction of recombinant proteins from Nicotiana leaf tissues can be achieved by collection of secreted protein fractions, or from a total protein extract after grinding the leaves with buffer. After separation from solids, the major purification challenge is contamination with elements of the photosynthetic complex, which can be solved by application of a variety of facile and proven strategies. In conclusion, the technologies required for safe, efficient, scalable manufacture of recombinant proteins in Nicotiana leaf tissues have matured to the point where several products have already been tested in phase I clinical trials and will soon be followed by a rich pipeline of recombinant vaccines, microbicides, and therapeutic proteins.
Collapse
|
8
|
Alderborn A, Sundström J, Soeria-Atmadja D, Sandberg M, Andersson HC, Hammerling U. Genetically modified plants for non-food or non-feed purposes: straightforward screening for their appearance in food and feed. Food Chem Toxicol 2009; 48:453-64. [PMID: 20004226 DOI: 10.1016/j.fct.2009.10.049] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2009] [Revised: 10/06/2009] [Accepted: 10/30/2009] [Indexed: 01/17/2023]
Abstract
Genetically modified (GM) plants aimed at producing food/feed are part of regular agriculture in many areas of the World. Commodity plants have also found application as bioreactors, designated non-food/non-feed GM (NFGM) plants, thereby making raw material for further refinement to industrial, diagnostic or pharmaceutical preparations. Many among them may pose health challenge to consumers or livestock animals, if occurring in food/feed. NFGM plants are typically released into the environment, but are grown under special oversight and any among several containment practices, none of which provide full protection against accidental dispersal. Adventitious admixture with food or feed can occur either through distributional mismanagement or as a consequence of gene flow to plant relatives. To facilitate NFGM surveillance we propose a new mandatory tagging of essentially all such plants, prior to cultivation or marketing in the European Union. The suggested tag--Plant-Made Industrial or Pharmaceutical Products Tag (PMIP-T)--is envisaged to occur as a transgenic silent DNA identifier in host plants and designed to enable technically simple identification and characterisation of any NFGM. Implementation of PMIP-T would permit inexpensive, reliable and high-throughput screening for NFGM specifically. The paper outlines key NFGM prospects and challenges as well as the PMIP-T concept.
Collapse
Affiliation(s)
- A Alderborn
- Dept. of Genetics and Pathology, The Rudbeck Laboratory, Uppsala University, SE-75185 Uppsala, Sweden
| | | | | | | | | | | |
Collapse
|
9
|
Sharma AK, Sharma MK. Plants as bioreactors: Recent developments and emerging opportunities. Biotechnol Adv 2009; 27:811-832. [PMID: 19576278 PMCID: PMC7125752 DOI: 10.1016/j.biotechadv.2009.06.004] [Citation(s) in RCA: 112] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2009] [Revised: 06/15/2009] [Accepted: 06/16/2009] [Indexed: 12/18/2022]
Abstract
In recent years, the use of plants as bioreactors has emerged as an exciting area of research and significant advances have created new opportunities. The driving forces behind the rapid growth of plant bioreactors include low production cost, product safety and easy scale up. As the yield and concentration of a product is crucial for commercial viability, several strategies have been developed to boost up protein expression in transgenic plants. Augmenting tissue-specific transcription, elevating transcript stability, tissue-specific targeting, translation optimization and sub-cellular accumulation are some of the strategies employed. Various kinds of products that are currently being produced in plants include vaccine antigens, medical diagnostics proteins, industrial and pharmaceutical proteins, nutritional supplements like minerals, vitamins, carbohydrates and biopolymers. A large number of plant-derived recombinant proteins have reached advanced clinical trials. A few of these products have already been introduced in the market.
Collapse
Affiliation(s)
- Arun K Sharma
- Department of Plant Molecular Biology, University of Delhi South Campus, New Delhi 110021, India.
| | - Manoj K Sharma
- Department of Plant Molecular Biology, University of Delhi South Campus, New Delhi 110021, India
| |
Collapse
|